GDPT和CHOP方案一线治疗血管免疫母细胞T细胞淋巴瘤的疗效与安全性  

Efficacy and safety of GDPT and CHOP regimen as the first-line treatment for angioimmunoblastic T cell lymphoma

作　　者：钱思宇 杨万秋 侯户婷 吴少璇 王泽元 尹美凤 陈清江[1,2] 丁梦杰[1,2] 董萌[1,2] 朱利楠[1,2] 张明智[1,2] 张旭东[1,2] QIAN Siyu;YANG Wanqiu;HOU Huting;WU Shaoxuan;WANG Zeyuan;YIN Meifeng;CHEN Qingjiang;DING Mengjie;DONG Meng;ZHU Linan;ZHANG Mingzhi;ZHANG Xudong(Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052;Lymphoma Diagnosis and Treatment Center,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052;Department of Oncology,the Third Affiliated Hospital,Xinxiang Medical College,Xinxiang,Henan 453000)

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052 [2]郑州大学第一附属医院河南省淋巴瘤诊疗中心,郑州450052 [3]新乡医学院第三附属医院肿瘤科,河南新乡453000

出　　处：《郑州大学学报（医学版）》2020年第2期172-175,共4页Journal of Zhengzhou University(Medical Sciences)

基　　金：国家自然科学基金青年科学基金项目(81700187)。

摘　　要：目的:总结GDPT方案与CHOP方案一线治疗血管免疫母细胞T细胞淋巴瘤(AITL)的疗效及安全性。方法:36例AITL患者,其中22例接受GDPT方案化疗2~8个周期,14例接受CHOP方案化疗3~8个周期。结果:GDPT组完全缓解(CR)或未确认完全缓解(CRu)5例,部分缓解(PR)11例,稳定(SD)4例,疾病进展(PD)2例;CHOP分别为2、5、2、5例,两组疗效差异无统计学意义(Z=1.528,P=0.127)。两组不良反应发生情况差异无统计学意义,经对症支持治疗后逐渐恢复。GDPT组随访10~51个月,2例死于感染,3例死于肿瘤进展。CHOP组随访3~43个月,1例死于感染,1例死于心力衰竭合并感染,2例死于肿瘤进展。两组总生存和无进展生存曲线差异均无统计学意义(χ^2=0.090、0.323,P=0.765、0.570)。结论:GDPT方案一线治疗AITL较CHOP方案未有明显的生存获益,有待进一步探索新的治疗方式。Aim:To evaluate the efficacy and safety of GDPT and CHOP chemotherapy as the first-line treatment for angioimmunoblastic T cell lymphoma(AITL).Methods:A total of 36 newly diagnosed AITL patients were retrospectively analyzed.Among them,22 were treated with GDPT(gemcitabine,cisplatin,prednisone,thalidomide)regimen for 2-8 cycles and 14 with CHOP(cyclophosphamide,adriamycin,vincristine,prednisone)regimen for 3-8 cycles.Results:There were 5 cases with CR or CRu,11 cases with PR,4 cases with SD,and 2 cases with PD in GDPT group,while 2,5,2,5 cases in CHOP group;and there was no difference in the efficacy between the two groups(Z=1.528,P=0.127).The adverse reaction incidence of the two groups had no difference,and the patients recovered gradually after symptomatic and supportive treatment.GDPT group was followed up for 10-51 months,2 cases died of infection and 3 cases died of tumor progression.CHOP group was followed up for 3-43 months,1 case died of infection,1 case died of heart failure complicated with infection,and 2 cases died of tumor progression.There were no significant differences in OS or PFS survival curves between the two groups(χ^2=0.090,0.323;P=0.765,0.570).Conclusion:GDPT regimen could not achieve favorable efficacy for AITL compared with CHOP regimen.Further therapeutic options are required to improve the outcome.

关 键 词：血管免疫母细胞T细胞淋巴瘤 GDPT方案 CHOP方案 

分 类 号：R733.4[医药卫生—肿瘤]